Cerity Partners LLC lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 38.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,899 shares of the medical research company's stock after acquiring an additional 19,203 shares during the period. Cerity Partners LLC's holdings in Agilent Technologies were worth $9,477,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Flynn Zito Capital Management LLC grew its stake in shares of Agilent Technologies by 3.8% during the 4th quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company's stock worth $251,000 after acquiring an additional 69 shares in the last quarter. IFP Advisors Inc grew its position in Agilent Technologies by 17.7% in the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company's stock valued at $62,000 after purchasing an additional 69 shares in the last quarter. Tiemann Investment Advisors LLC increased its stake in Agilent Technologies by 5.6% in the 4th quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company's stock valued at $191,000 after buying an additional 75 shares during the last quarter. Rothschild Investment LLC lifted its position in Agilent Technologies by 19.2% during the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company's stock worth $66,000 after buying an additional 79 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of Agilent Technologies by 1.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company's stock worth $1,025,000 after buying an additional 87 shares during the last quarter.
Analysts Set New Price Targets
A number of research firms recently issued reports on A. TD Cowen lifted their target price on Agilent Technologies to $135.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Citigroup upped their price objective on Agilent Technologies to $165.00 and gave the stock a "buy" rating in a research note on Thursday, December 19th. StockNews.com raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Barclays cut their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Finally, Robert W. Baird cut their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $146.25.
Check Out Our Latest Report on A
Agilent Technologies Stock Performance
Shares of A stock traded up $0.44 on Wednesday, hitting $103.56. The company's stock had a trading volume of 401,548 shares, compared to its average volume of 2,066,778. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. The company has a market capitalization of $29.52 billion, a PE ratio of 23.81, a PEG ratio of 2.96 and a beta of 1.19. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $155.35. The stock's 50 day moving average is $122.01 and its 200-day moving average is $133.33.
Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The firm had revenue of $1.68 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. Equities research analysts expect that Agilent Technologies, Inc. will post 5.55 earnings per share for the current fiscal year.
Agilent Technologies Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.96%. Agilent Technologies's payout ratio is 22.76%.
Insider Buying and Selling at Agilent Technologies
In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of the business's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the transaction, the director now owns 35,737 shares of the company's stock, valued at approximately $4,161,931.02. The trade was a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Padraig Mcdonnell sold 1,911 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now owns 39,652 shares in the company, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,638 shares of company stock valued at $731,229 in the last ninety days.
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
